Faculty Advisor
Abdulhadi Abdulwahed
Faculty Advisor
Helen Tempest
Faculty Advisor
Helen Tempest
Start Date
8-4-2019 10:00 AM
End Date
8-4-2019 12:00 PM
Session
Poster Session 1
Abstract
Ovarian cancer is aggressive, silent (hidden for the majority of its development) and often resistant to cisplatin chemotherapy. Often, each cancer type has unique aneuploidy and gene repositioning, but patterns prevail; therefore, the focus of this study is to find the differences in patterns between sensitive and resistant ovarian cancer cells. If cells are resistant to cisplatin chemotherapy, then they will have specific gene repositioning and an increase in ploidy. Fluorescent In Situ Hybridization (FISH) will be utilized to track repositioning and count ploidy on three different ovarian cell lines, two sensitive to cisplatin and one resistant. Twenty-two different commercially manufactured fluorescent probes will attach to corresponding genes in the DNA of the ovarian cell in pairs. Microscopes and software with the help of the probes allow visualization of the desired genes in vitro. Ovarian cancer took 14,000 lives last year while the surviving 8,000 had a 75% reoccurrence rate which is often accompanied by chemotherapy resistance. Patterns within individual cancers exist and have been used for diagnosis and better understanding of the most effective chemotherapy in other cancers. Ovarian cancer is often undiagnosed until it has progressed to an advanced stage. When ovarian cancer reaches an advanced stage, 70-80% become resistant to platinum-based chemotherapy, like cisplatin. Using FISH to understand if gene repositioning or cell ploidy enables a cell to become resistant will make future diagnoses more efficient. If doctors can determine that the cancer will be resistant to cisplatin chemotherapy based on the gene count or position, then the patient can be redirected to other medication, saving time and increasing chances of survival. Ovarian cancer is commonly treated with cisplatin chemotherapy and as ovarian cancer is typically caught very late in the progression, any time saved is important.
File Type
Poster
Gene Positioning in Chemosensitive and Chemoresistant Ovarian Cancer Cell Lines
Ovarian cancer is aggressive, silent (hidden for the majority of its development) and often resistant to cisplatin chemotherapy. Often, each cancer type has unique aneuploidy and gene repositioning, but patterns prevail; therefore, the focus of this study is to find the differences in patterns between sensitive and resistant ovarian cancer cells. If cells are resistant to cisplatin chemotherapy, then they will have specific gene repositioning and an increase in ploidy. Fluorescent In Situ Hybridization (FISH) will be utilized to track repositioning and count ploidy on three different ovarian cell lines, two sensitive to cisplatin and one resistant. Twenty-two different commercially manufactured fluorescent probes will attach to corresponding genes in the DNA of the ovarian cell in pairs. Microscopes and software with the help of the probes allow visualization of the desired genes in vitro. Ovarian cancer took 14,000 lives last year while the surviving 8,000 had a 75% reoccurrence rate which is often accompanied by chemotherapy resistance. Patterns within individual cancers exist and have been used for diagnosis and better understanding of the most effective chemotherapy in other cancers. Ovarian cancer is often undiagnosed until it has progressed to an advanced stage. When ovarian cancer reaches an advanced stage, 70-80% become resistant to platinum-based chemotherapy, like cisplatin. Using FISH to understand if gene repositioning or cell ploidy enables a cell to become resistant will make future diagnoses more efficient. If doctors can determine that the cancer will be resistant to cisplatin chemotherapy based on the gene count or position, then the patient can be redirected to other medication, saving time and increasing chances of survival. Ovarian cancer is commonly treated with cisplatin chemotherapy and as ovarian cancer is typically caught very late in the progression, any time saved is important.
Rights Statement
In Copyright. URI: http://rightsstatements.org/vocab/InC/1.0/
This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).
Comments
**Abstract Only**